Miami man pleads guilty to selling adulterated, misbranded HIV drugs across U.S.

Must read

Bank CEO shrugs off U.S. war on ‘woke’ capital, says ESG investing is good for business

Bill Winters, Chief Executive Officer at the Standard Chartered Bank, attends a panel session of the World Governments Summit in Dubai on February 12,...

Russia offering African governments ‘regime survival package’ in exchange for resources, report says

OUAGADOUGOU, Burkina Faso - Jan. 20, 2023: A banner of Russian President Vladimir Putin is seen during a protest to support the Burkina Faso...

Smartphone makers are dreaming of a ‘supercycle’ driven by AI. Analysts disagree

Samsung Electronics' flagship smartphones Galaxy S24 series are displayed during their unveiling ceremony in Seoul, South Korea, January 15, 2024. Kim Hong-ji | ReutersBARCELONA –...

The 11 GRANOLAS stocks power Europe to record highs, drawing Magnificent Seven comparisons

The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 19, 2024. Staff | ReutersOver the last 12...

A Miami man has pleaded guilty in federal court to distributing adulterated HIV drugs dispensed to U.S. patients.

Miami Herald | Tribune News Service | Getty Images

A Miami man pleaded guilty to distributing as much as $25 million worth of misbranded and adulterated HIV drugs that were dispensed by pharmacies across the U.S. to unsuspecting patients, federal prosecutors said.

Armando Herrera, 43, faces a maximum possible sentence of five years in prison for the crime.

Herrera pleaded guilty in U.S. District Court in Miami on Monday to one count of conspiracy to introduce adulterated and misbranded drugs in the U.S. market, court filings show.

A medication is adulterated if a substance has been substituted for the drug in whole or in part.

Herrera and his co-conspirators set up companies in Texas, California and Washington state that acquired large quantities of misbranded and adulterated HIV medication from legal channels, falsified the pills’ packaging and sold them at a steep discount to wholesalers that later sold them to pharmacies, court documents say.

Prosecutors said the wholesalers were involved in the criminal scheme, but the pharmacies were unaware that the drugs were altered or misbranded.

The adulterated and misbranded drugs included Truvada, Biktarvy and other unnamed medications.

Truvada is prescribed to prevent HIV infection in people who are at risk of contracting the virus. The medication is also used in combination with other drugs to treat infection.

Biktarvy is prescribed to treat HIV infection. Truvada and Biktarvy are manufactured by Gilead Sciences.

Herrera and his co-conspirators received between $16.7 million and $25 million in payment from two wholesalers, according to court filings.

The filings did not say how Herrera and his co-conspirators acquired the drugs.

Medications are often siphoned off the legal market by purchasing them from individual patients who were prescribed the drugs.

Herrera is scheduled to be sentenced Dec. 21. His lawyer did not immediately respond to CNBC’s request for comment.

More articles

Latest article

Bank CEO shrugs off U.S. war on ‘woke’ capital, says ESG investing is good for business

Bill Winters, Chief Executive Officer at the Standard Chartered Bank, attends a panel session of the World Governments Summit in Dubai on February 12,...

Russia offering African governments ‘regime survival package’ in exchange for resources, report says

OUAGADOUGOU, Burkina Faso - Jan. 20, 2023: A banner of Russian President Vladimir Putin is seen during a protest to support the Burkina Faso...

Smartphone makers are dreaming of a ‘supercycle’ driven by AI. Analysts disagree

Samsung Electronics' flagship smartphones Galaxy S24 series are displayed during their unveiling ceremony in Seoul, South Korea, January 15, 2024. Kim Hong-ji | ReutersBARCELONA –...

The 11 GRANOLAS stocks power Europe to record highs, drawing Magnificent Seven comparisons

The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 19, 2024. Staff | ReutersOver the last 12...

eToro wants to bring its trading app to Apple Vision Pro and Meta Quest headsets

An Apple Vision Pro mixed reality (XR) headset is seen at Apple store in New York, United States on Feb. 3, 2024.Fatih Aktas |...